

Pseudomembranous colitis with Clostridium difficile during treatment by moxifloxacine (quinolone).

Le Goff C, Wiesen P, Collette J, Preiser JC, Kaux JF, De Mol P Department of Clinical Biology, Microbiology Laboratory, CHU of Liège, Belgium



Fig. 9 : Cellular culture.


C. difficile is the most frequently pathogenic agent isolated in colitis associated with antibiotics and pseudomembranous colitis (PMC). C. difficile takes advantage of the disturbance of the intestinal


We report a case of PMC appeared during treatment with moxifloxacine in a pulmonary infection in an emphysematous patient

The diarrhea is generally benign, but can be severe, with toxic megacolon or even the extreme case of

The diagnosis is based on the research of toxins of C. difficile (A and/or B) in the intestinal stools or liquids (collected at the time of the endoscopic examination) to which is associated the anaerobic culture on selective agar. The reference method is the measurement of the cytotoxic effect of the Btoxin on a cell culture.

Metronidazole or vancomycine constitutes the treatment.





Relapse prevention: association of probiotic agents (eg: Saccharomyces boulardi) with AB. Prevention of nosocomial infections: hygiene + isolment of the patient + room decontamination.

Relapse

CONCLUSION

- · C. difficile is a major nosocomial pathogen.
- · C. difficile transmission from patient to patient is frequent but often remains asymptomatic
- Environment can act as a reservoir.
- Microbiological diagnosis is easy.
- Surveillance should be instituted in order to detect relapses.